加载中
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
常规交易时段
US$2.86
−US$0.16 · -5.30%
盘中时间采用ET。市场数据可能有所延迟。
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
日内区间
当前US$2.86
52周区间
当前US$2.86
盘中时间采用ET。市场数据可能有所延迟。
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
日内区间
当前US$2.86
52周区间
当前US$2.86
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | 43.14万 USD | 129.6万 USD | 154.2万 USD |
| 销货成本 | — | 25.5万 USD | 42.08万 USD | 121.6万 USD | 146万 USD |
| 毛利 | — | −25.5万 USD | 1.06万 USD | 8.01万 USD | 8.19万 USD |
| 研究与开发 | 35.29万 USD | 194.4万 USD | 519.8万 USD | 922万 USD | 1087万 USD |
| 销售、一般及管理费用 | 163.54万 USD | 146.9万 USD | 441.5万 USD | 796.5万 USD | 802.7万 USD |
| 营业费用 | 181.75万 USD | 354.1万 USD | 1061.2万 USD | 1725.4万 USD | 1928.9万 USD |
| 利息收入 | — | — | — | 14.66万 USD | — |
| 利息支出 | 9.57万 USD | 14.69万 USD | 12.11万 USD | — | 9.36万 USD |
| 折旧和摊销 | — | 30.56万 USD | 137.76万 USD | 155.65万 USD | 119.26万 USD |
| 营业利润 | −181.75万 USD | −379.6万 USD | −1060.1万 USD | −1750.91万 USD | −1920.7万 USD |
| 净利润 | −136.33万 USD | −426.8万 USD | −282.5万 USD | −980万 USD | −2504.8万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
